Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Imunon looks for an IL-12 Ovation
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
The first clinical-stage dual-payload conjugate
Chengdu Kanghong's KH815 enters human testing this month.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
